Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- US Biotech Acucela Makes Debut on TSE’s Mothers Market
February 18, 2014
- MTPC, JB to End Copromotion of Blood Plasma Products
February 18, 2014
- Nissan Chemical Sues Three More Generic Makers over Livalo Patent Infringement
February 18, 2014
- Daiichi Sankyo, UMN Pharma Sign Collaborative Research Deal for Norovirus Vaccine
February 18, 2014
- Blopress AGs Approved, Yet Blurry Prospect for Their June Listing
February 17, 2014
- Kissei, Alteogen Agree on Business Collaboration for Biosimilar Development
February 17, 2014
- LEO Pharma’s New Japan Head Takes Office
February 17, 2014
- Once-Monthly Injectable Abilify Maintena Approved in Canada: Otsuka, Lundbeck
February 17, 2014
- New Suspicion Hints Close Link between Novartis, SIGN Initiator Group
February 17, 2014
- Nichi-Iko on Tap to Enter US Market, Remicade Biosimilar Debut Eyed around 2018
February 14, 2014
- Qol to Introduce Bidding System for Drug Purchasing Aimed at Avoiding Reduction in Basic Dispensing Fees Received
February 14, 2014
- Ex-Bellsystem24 Exec Deguchi to Spearhead AbbVie Japan
February 13, 2014
- Kyowa Kirin Temporarily Drops Untreated ATL Indication for Poteligeo
February 13, 2014
- Kaken Licenses Container Technology for Efinaconazole to Valeant
February 13, 2014
- AnGes Sales Up 10.5% but Logs 1,409 Million Yen Net Loss in 2013
February 12, 2014
- Ethical Drug Sales Up 4.7% in December: Crecon Report
February 12, 2014
- Asahi Kasei Pharma Completes 2nd Manufacturing Facility at Nagoya Pharmaceuticals Plant
February 12, 2014
- Novartis Appoints Former Tokyo High Court Judge to Head Independent Commission to Investigate Scandal Over SIGN Study
February 10, 2014
- Transdermal Parkinson’s Disease Treatment Ropinirole Shows Significant Difference in PII Study: Hisamitsu
February 10, 2014
- Mitsubishi Chemical to Set Up New Healthcare Firm
February 7, 2014
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…